OptiBiotix Health PLC Presentation of research data at ProBiota 2017
January 12 2017 - 1:00AM
RNS Non-Regulatory
TIDMOPTI
OptiBiotix Health PLC
12 January 2017
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Presentation of research data at European Conference: ProBiota
2017
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces that it has had two abstracts accepted for
presentation at ProBiota 2017 in Berlin from 1-3 February 2017.
ProBiota is the leading annual event for the global prebiotic,
probiotic and the microbiota focused food and pharma industries.
The conference is world renowned as a key meeting place for a
community of scientists and business leaders who want to translate
science into new products in the growing supplements and
ingredients market.
The two abstracts relate to the work the Company has undertaken
on its cholesterol lowering probiotic. The first abstract will
cover the results of the clinical study and will be presented as a
poster and oral presentation. The second abstract will be presented
as a poster and covers the work on species specific microbiome
modulators which the Company has used to enhance the cholesterol
reducing effect of their cholesterol reducing strain (LP-LDL(R)).
In the case of this strain, it leads to a threefold increase in the
strains ability to lower cholesterol.
Commenting, Stephen O'Hara, CEO of OptiBiotix said: "These
publications, at a major conference, will support the launch of a
range of cardiovascular products to reduce LDL cholesterol, blood
pressure and cardiovascular risk, planned for the spring of 2017.
The publications will provide the scientific evidence for sales and
marketing literature, which will help with product differentiation
and higher margins. In order to provide us with wider coverage of
our scientific advances in both the scientific and mainstream news
media, we have appointed a specialist scientific PR company, Vane
Percy & Roberts to help with this."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213
0883
Liam Murray
finnCap (Broker) Tel: 020 7220
0500
Adrian Hargrave / Scott Mathieson
/ Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876
741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRASFFFMFFWSEFF
(END) Dow Jones Newswires
January 12, 2017 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024